Exhibit 10.4(e)

 

This Amendment No. 5 to the Research, License and Royalty Agreement (the
“Amendment”) is entered into by and between Pharmacopeia, Inc. (“Pharmacopeia”)
and Berlex Laboratories, Inc. (“Berlex”), and amends the Research, License and
Royalty Agreement between Berlex and Pharmacopeia dated February 15, 1995 (“the
1995 Agreement”), as previously amended in Amendment Nos. 1 through 4.

 

1.             [*]

 

2.                                      Subject to paragraph 5 of this
Amendment, the milestone and royalty payments specified in Section VI and VII of
the 1995 Agreement shall be replaced by the following paragraphs 2 and 3:

 

2.1           Within [*] of receipt by Berlex of [*].

 

--------------------------------------------------------------------------------

* Information omitted and filed separately with the Commission under Rule 24b-2.

 

--------------------------------------------------------------------------------

 

2.2           Within [*] of receipt by Berlex of [*]

 

2.3                                  2.3         Subject to paragraph 4 of this
Amendment, Berlex shall also make the following payments [*]:

 

2.3.1 Filing of an IND: [*]

 

2.3.2 Start of a Phase III Study: [*]

 

2.3.3 Filing of an NDA: [*]; and

 

2.3.4 First Commercial Sale: [*]

 

For the avoidance of doubt, with respect to any compounds [*], the foregoing
milestone payments will be paid only once irrespective of the number of products
containing [*], or the number of [*], that achieve the milestone.

 

3.             With respect to any compounds [*], subject to paragraph 4 of this
Amendment, Berlex shall pay to Pharmacopeia [*].

 

4.             The milestone and royalty payments set forth in paragraphs 2.3.2,
2.3.3, 2.3.4 and 3 hereof will be payable to Pharmacopeia [*]

 

5.             [*]

 

2

--------------------------------------------------------------------------------

 

 

 

6.                   Berlex has the right to [*].

 

7.                   To the extent reasonably necessary for Pharmacopeia to
comply with SEC reporting requirements Berlex agrees to issue joint press
releases with Pharmacopeia within thirty (30) days of each of the following
events: (a) the effective date [*]; and (b) Pharmacopeia’s receipt of milestone
payments as described in this Amendment.

 

Except as expressly stated in this Amendment, all other terms and conditions of
the 1995 Agreement, including the meanings of all capitalized terms, shall
remain in full force and effect.  In the event of any inconsistency between the
terms of this Amendment and the Agreement, the terms of this Amendment will
prevail.

 

IN WITNESS WHEREOF, each of the Parties has executed this Amendment as of the
dates indicated below.

 

Berlex Laboratories, Inc.

Pharmacopeia, Inc.

 

 

 

 

/s/ Lutz Lingnau

 

/s/ Michael G. Lenahan

 

Signature

 

Signature

 

 

 

 

 

1-24-03

 

1-20-03

 

Date

 

Date

 

 

 

 

3

--------------------------------------------------------------------------------